Geoffrey Porges, a longtime biotech analyst and well-known Wall Street figure, stepped down as CFO of the New York biotech ...

Volastra reports promising Phase 1/2 data for VLS-1488 in solid tumors, with good safety and early efficacy signals in ...

Jazz's Zepzelca + Roche's Tecentriq shows 27% reduced death risk & improved survival in lung cancer trial; FDA application ...

GSK’s blockbuster respiratory drug Nucala was approved Thursday for certain patients with chronic obstructive pulmonary ...

FDA Commissioner Marty Makary defended thousands of staff cuts during his first congressional hearing since taking office, ...

Cigna on Wednesday said it negotiated with Novo Nordisk and Eli Lilly to secure deeper GLP-1 drug discounts for employers ...

The House of Representatives on Thursday passed President Donald Trump’s tax cut package, with steep Medicaid cuts, PBM ...

The White House released its first MAHA Commission report, detailing some of the Trump administration’s top priorities for ...

Endpoints News announces URL change from endpts.com to endpoints.news effective June 1, 2025, with legacy redirects planned ...

After a median 34.2 months of follow-up, patients taking Itovebi in combination with Pfizer’s Ibrance and AstraZeneca’s Faslodex survived for a median of 34 months, compared to 27 months for those ...

Beam Therapeutics CEO John Evans warns against AI hype in drug development, drawing parallels to past CRISPR expectations, ...

Sanofi will acquire Vigil for its oral small molecule TREM2 project, dubbed VG-3927, that is on tap for a Phase 2 in ...